Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27606784 | 0.86 | PTGS1 (0.56) | PTGS1PTGS2L3MBTL1POLBMTNR1A | |
| SCHEMBL28121831 | 0.85 | PTGS1 (0.56) | PTGS1PTGS2L3MBTL1TDP1MTNR1A | |
| SCHEMBL27484110 | 0.85 | PTGS1 (0.49) | PTGS1PTGS2L3MBTL1TDP1POLB | |
| SCHEMBL3918115 | 0.85 | L3MBTL1 (0.55) | PTGS1L3MBTL1TDP1POLBMTNR1A | |
| SCHEMBL5110018 | 0.85 | PTGS1 (0.74) | PTGS1PTGS2L3MBTL1MEN1KMT2A | |
| SCHEMBL8755064 | 0.85 | PTGS1 (0.74) | PTGS1PTGS2L3MBTL1MEN1KMT2A | |
| SCHEMBL8455849 | 0.84 | L3MBTL1 (0.54) | L3MBTL1TDP1POLBTHRBMTNR1A | |
| SCHEMBL16800683 | 0.84 | PTGS1 (0.58) | PTGS1PTGS2L3MBTL1POLBMTNR1A | |
| SCHEMBL15641441 | 0.84 | PTGS1 (0.73) | PTGS1PTGS2L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL31635557 | 0.84 | PTGS1 (0.73) | PTGS1PTGS2L3MBTL1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019196803-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2019-10-17 | — | — | WO | disclosed |
| CN-107406426-A | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7282618-B2 | Method for the production of aryl alkenes | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-10-16 | — | — | US | disclosed |
| EP-1351901-A4 | METHOD FOR THE PRODUCTION OF ARYL ALKENES | YEDA RES & DEV (IL) | 2006-05-31 | — | — | EP | disclosed |
| US-20040073075-A1 | Method for the production of aryl alkenes | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2004-04-15 | — | — | US | disclosed |
| EP-1351901-A1 | METHOD FOR THE PRODUCTION OF ARYL ALKENES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055455-A1 | METHOD FOR THE PRODUCTION OF ARYL ALKENES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-07-18 | — | — | WO | disclosed |
| WO-1998031697-A1 | ARYL C-GLYCOSIDE COMPOUNDS AND SULFATED ESTERS THEREOF | SANKYO COMPANY, LIMITED (JP) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073075-A1 | Method for the production of aryl alkenes | AOC2, AOX1, AOC3 | PTGS1 1891/4885PTGS2 1042/4885L3MBTL1 3459/4885 |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | PTGS1 2471/4885PTGS2 1864/4885L3MBTL1 4543/4885 |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | ADORA2A, ADORA3, ADORA2B | PTGS1 2471/4885PTGS2 1864/4885L3MBTL1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.